Abstract
Our findings indicate that a hydrogel-based bacterial delivery system is a safe and effective approach for the treatment of abdominal metastases.
Introduction
Peritoneal metastasis, the spread of cancer throughout the abdominal cavity lining, remains a critical challenge in treating advanced colorectal and gastric cancers. Conventional intravenous chemotherapy often fails to achieve therapeutic concentrations within the abdomen without inducing systemic toxicity. While immunotherapy offers a promising alternative, the abdominal tumor microenvironment (TME) is typically immunosuppressive, or "cold," shielding cancer cells from immune detection. Although genetically engineered bacteria can stimulate an immune response, they are rapidly cleared when administered as a "naked" drug. This study addresses these challenges by developing a localized, sustained delivery system for immune activation.
Methods and Materials
The researchers developed a dual-component system consisting of a payload and a delivery vehicle. The payload is a genetically engineered strain of Mycobacterium smegmatis (Ms-IL15) designed to express Interleukin-15 (IL-15), a cytokine that activates T cells and Natural Killer (NK) cells. The vehicle is Poloxamer 407 (P407), a biocompatible, thermosensitive hydrogel that remains liquid at room temperature but solidifies at body temperature (37°C).
The system was characterized using Scanning Electron Microscopy (SEM) to confirm its porous structure, which facilitates bacterial adherence and controlled release. In vivo efficacy was evaluated using murine models of peritoneal metastasis (MC38 colon cancer and H22 liver cancer). Tumor progression was monitored via bioluminescence imaging, and the local immune response was analyzed using multi-color flow cytometry.
Key Insights: Reprogramming the Tumor Microenvironment
The P407/Ms-IL15 system functions as an "immune factory" or reservoir within the abdominal cavity. Fluorescence imaging demonstrated that while naked bacteria were cleared within 28 days, the hydrogel-encapsulated bacteria remained active at the site for the same duration.
This sustained presence effectively "warmed up" the cold TME by:
- Enhancing Dendritic Cell (DC) Maturation: Increasing DC maturation by approximately 2.8-fold, improving antigen presentation.
- Boosting Effector Memory T cells (TEM): Promoting long-term immune surveillance.
- Modulating Macrophage Polarization: Reducing the proportion of pro-tumor M2 macrophages.
Results
The therapeutic impact was significant across multiple metrics:
- Tumor Suppression: In the MC38 model, the average tumor weight in the hydrogel-treated group was ~345mg, compared to ~2500mg in control groups—a nearly 8-fold reduction.
- Survival Extension: 100% of mice treated with the P407/Ms-IL15 system survived to the 60-day endpoint, whereas all control mice died within 30 days.
- Ascites Control: In the H22 model, the volume of malignant ascites was reduced by approximately 2.5 times compared to saline controls.
- Immune Activation: Flow cytometry confirmed a significant increase in Granzyme B expression in CD8+ T cells, indicating enhanced cytotoxic capacity.
Discussion and Future Directions
The study demonstrates that localized delivery of engineered bacteria via a thermosensitive hydrogel is a safe and effective strategy for treating abdominal metastases. By confining the bacteria and IL-15 to the abdomen, the researchers achieved high efficacy without systemic organ damage.
Future work will focus on optimizing the P407 concentration for human applications to balance stability and biocompatibility. Additionally, exploring synergies between this hydrogel system and existing treatments, such as checkpoint inhibitors (e.g., anti-PD-1), could further enhance therapeutic outcomes. While tested in two mouse models, further research is needed to validate this approach across a broader range of abdominal cancers.
Summary updated